Phase 4 N=42 Efficacy of Interscalene Brachial Plexus Block With Liposomal Bupivacaine for Arthroscopic Shoulder Surgery
Shoulder Pain · Rotator Cuff Tear
Primary: Total Opioid Consumption — 2; 2.75; 1.94; 3.33 number of percocet tabs
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 4 N=102 The Effect of NSAID Use in the Acute Phase of Skeletally Immature Bone Healing: A Prospective Study
Fractures
Primary: Compare the Time to Union of Fractures and Osteotomies in Skeletally Immature Patients Administered NSAIDs for Pain Control, Versus Those Administered Acetaminophen for…
N/A N=70 A Cost Effective Treatment for Headache in Pregnancy When Acetaminophen Alone is Ineffective.
Headache
Primary: Number of Participants With Adequate Relief of Headache as a Measure of Efficacy — 34; 32 Participants — p=0.14
Phase 3 N=398 Sarizotan in Participants With Parkinson's Disease Suffering From Treatment Associated Dyskinesia
Parkinson's Disease · Dyskinesia
Primary: Change From Baseline in Diary-Based On-Time Without Dyskinesia at Week 12 — 1.6; 1.9; 1.7; 1.8 hours/day
Phase 3 N=813 Efficacy and Safety of Semaglutide Once-weekly Versus Exenatide ER 2.0 mg Once-weekly as add-on to 1-2 Oral Antidiabetic Drugs (OADs) in Subjects With Type 2 Diabetes
Diabetes · Diabetes Mellitus, Type 2
Primary: Change From Baseline in HbA1c (Glycosylated Haemoglobin) — -1.54; -0.92 percentage of glycosylated haemoglobin — p=< 0.0001
Phase 2 N=122 Dolutegravir Plus Lamivudine Dual Therapy in Treatment Naïve HIV-1 Patients
HIV-1 Infection
Primary: Virologic Status at Week 24 — 108; 5; 7 Participants
Phase 4 N=106 Effectiveness of Rebif® in Clinically Isolated Syndrome and Relapsing Multiple Sclerosis Using RebiSmart™
Relapsing Multiple Sclerosis · Clinically Isolated Syndrome
Primary: Percentage of Relapse-free RMS Subjects — 66.3 percentage of subjects
Phase 3 N=133 Subcutaneous Testosterone Enanthate Safety in Adult Men Diagnosed With Hypogonadism
Hypogonadism
Primary: Incidence of Adverse Events as a Measure of Safety of QuickShot™ Testosterone (QST) Administered Subcutaneously (SC) Once Each Week to Adult Males With Hypogonadism…
Phase 2 N=855 A Study To Investigate Two 3-dose Schedules Of A Clostridium Difficile Vaccine In Healthy Adults Aged 65 to 85 Years
Clostridium Difficile Associated Disease
Primary: Day 1, 8 and 30 Regimen: Percentage of Participants Achieving Prespecified Antibody Titer Level for Toxin A at Day 37 — 12.5; 68.4; 85.5 percentage of participants
Phase 1 N=44 Sofosbuvir-Containing Regimens Without Interferon For Treatment of Acute Hepatitis C Virus (HCV) Infection
HIV-1 Infection · Hepatitis
Primary: Percentage of Participants With Sustained Virologic Response 12 (SVR12) — 58.8; 100.0 Percentage of participants
N/A N=74 Dysphagia Following Anterior Cervical Spine Surgery; Steroid vs Saline
Dysphagia
Primary: Swallowing Difficulty — 16; 14; 5; 7 Participants — p=0.036
N/A N=4,313 Length of Stay in NVAF Patients Hospitalized and Initiated With Dabigatran or Warfarin in Japan
Atrial Fibrillation
Primary: Length of Stay (LoS) From Treatment of Oral Anticoagulant Initiation to Hospital Discharge Without Consideration of Baseline — 9.8; 14.9 Months — p=<0.001
Phase 4 N=166 Safety and Efficacy of Pre-defined, Fixed Dose of Gonal-f Pen Based on Subject Baseline Characteristics in Subjects Undergoing in Vitro Fertilization (IVF)
Infertility
Primary: Number of Oocytes Retrieved — 8.3; 9.6; 12.1; 12.7 Oocytes
Phase 3 N=6,545 Efficacy, Safety and Tolerability of Serelaxin When Added to Standard Therapy in AHF
Acute Heart Failure
Primary: Percentage of Participants With Confirmed Cardiovascular (CV) Death Through Day 180 — 8.7; 8.9 Percentage of participants — p=0.3857
Phase 3 N=1,070 Blacks and Exacerbations on Long Acting Beta Agonists (LABA) vs. Tiotropium (BELT)
Asthma
Primary: Time to Asthma Exacerbation (Mean Number of Exacerbations/Person-year) — 0.37; 0.42 event per person-year — p=0.31